Chris Wertz, Ph.D.

Senior Vice President, Pharmaceutical Sciences

Nanocopoeia Pipeline

Drug	Indication	Phase
Undisclosed 505(b)(2) Programs	Various (targeting low solubility drugs)	Pre-clinical